Eli Lilly Stock Jump Looks Great, But How Secure Is That Gain?

LLY: Eli Lilly logo
LLY
Eli Lilly

Eli Lilly (LLY) stock is up 25.3% in 21 trading days. The rally reflects robust sales of its GLP-1 drugs and a strong pipeline, but big moves like this often invite a tougher question: is the stock truly resilient when markets reverse?

Before judging its downturn reslience, let’s look at where Eli Lilly stands today.

  • Size: Eli Lilly is a $921 Bil company with $53 Bil in revenue currently trading at $1,025.28.
  • Fundamentals: Last 12 month revenue growth of 36.8% and operating margin of 43.0%.
  • Liquidity: Has Debt to Equity ratio of 0.04 and Cash to Assets ratio of 0.04
  • Valuation: Eli Lilly stock is currently trading at P/E multiple of 66.7 and P/EBIT multiple of 51.8

These metrics point to a Very Strong operational performance, alongside Very High valuation – making the stock Attractive but Volatile.

That brings us to the key consideration for investors chasing this rally: how resilient is LLY stock if markets turn south? While we like to ride the momentum when the fundamentals check out (see Buy or Sell LLY Stock) – we stay wary of potential bull traps.

Relevant Articles
  1. GE Aerospace Stock To $284?
  2. Meta Platforms Stock To $838?
  3. Amphenol Stock To $168?
  4. Clear Secure Stock To $54?
  5. Modine Manufacturing Stock To $98?
  6. Stocks, Bonds, Gold, Crypto: Market Update 12/12/2025

This is where our downturn resilience framework comes in. Suppose LLY stock falls 20-30% to $718 – can investors comfortably hold on? Turns out, the stock saw an impact slightly better than the S&P 500 index during various economic downturns, based on (a) how much the stock fell and, (b) how quickly it recovered. While a single stock can excite, it rarely sustains. Financial advisors who win long term use disciplined allocation – blending equities, gold, and alternatives through trusted partners like ours.

Below are the details, but before that, as a quick background: LLY provides innovative pharmaceuticals globally, including treatments for cancer, rheumatoid arthritis, and autoimmune diseases such as psoriasis and ankylosing spondylitis.

2022 Inflation Shock

  • LLY stock fell 18.7% from a high of $272.71 on 17 August 2021 to $221.60 on 28 September 2021 vs. a peak-to-trough decline of 25.4% for the S&P 500.
  • However, the stock fully recovered to its pre-Crisis peak by 15 December 2021
  • Since then, the stock increased to a high of $1,025.28 on 16 November 2025 $1,025.28

  LLY S&P 500
% Change from Pre-Recession Peak -18.7% -25.4%
Time to Full Recovery 78 days 464 days

 
2020 Covid Pandemic

  • LLY stock fell 22.9% from a high of $169.13 on 8 July 2020 to $130.46 on 30 October 2020 vs. a peak-to-trough decline of 33.9% for the S&P 500.
  • However, the stock fully recovered to its pre-Crisis peak by 16 December 2020

  LLY S&P 500
% Change from Pre-Recession Peak -22.9% -33.9%
Time to Full Recovery 47 days 148 days

 
2018 Correction

  • LLY stock fell 18.5% from a high of $131.02 on 26 March 2019 to $106.79 on 19 July 2019 vs. a peak-to-trough decline of 19.8% for the S&P 500.
  • However, the stock fully recovered to its pre-Crisis peak by 20 December 2019

  LLY S&P 500
% Change from Pre-Recession Peak -18.5% -19.8%
Time to Full Recovery 154 days 120 days

 
2008 Global Financial Crisis

  • LLY stock fell 54.6% from a high of $60.56 on 20 April 2007 to $27.47 on 5 March 2009 vs. a peak-to-trough decline of 56.8% for the S&P 500.
  • However, the stock fully recovered to its pre-Crisis peak by 21 April 2014

  LLY S&P 500
% Change from Pre-Recession Peak -54.6% -56.8%
Time to Full Recovery 1873 days 1480 days

 
It is a good thing to keep in mind how low LLY could go during a downturn. And you should also check how the stock fared when compared with the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.